Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2012-04-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biopsy
two 2 mm gingival biopsies were obtained.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* be at the ages specified within age groups.
* male or female of the Caucasian race
* agree not to participate in any other oral/dental product studies during the course of this study.
* agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed.
* agree to return for all scheduled visits and follow study procedures.
* have at least 16 natural teeth (excluding wisdom teeth).
* be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study.
* healthy gingival tissue suitable for biopsy in the maxillary premolar area (per examiner discretion).
Exclusion Criteria
* smoking or smoking cessation \<1 year;
* any diseases or conditions to be expected to interfere with the examination or with the subject safely completing the study;
* history of drug use that is associated with gum overgrowth (i.e., dilantin, nifedipine, etc) or drugs that are known to inhibit salivary flow (i.e. antipsychotics etc.);
* chronic use of medication such as steroids, ibuprofen or acetylsalicylic acid (aspirin/ASA) more than 2-3 days/week), anti-coagulant medications, immunosuppressant medications or any other medications that in the opinion of the Investigator would interfere with the evaluation or confound interpretation of the study results. Use of low dose of ASA is permitted;
* previous gum surgery that might interfere with gum biopsy collection;
* presence or history of periodontal disease (at least 2 pockets 6mm);
* all teeth that are grossly carious, fully crowned, or extensively restored (per investigator discretion);
* any condition requiring the need for antibiotic pre-medication prior to dental procedures;
* current participation in any other oral/dental product studies;
* pregnancy or lactation;
* diabetes, autoimmune or infectious diseases, dry mouth, skin diseases;
* orthodontic appliances
20 Years
74 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Procter and Gamble
INDUSTRY
The Forsyth Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012007
Identifier Type: -
Identifier Source: org_study_id